CD20+cells blockage by rituximab delays wound healing in oral traumatic ulcers in rats

Objective: Wound healing of oral traumatic ulcers (OTU) is strongly associated with cytokines and inflammatory cells, and the reduction of anti-inflammatory cells, such as lymphocyte B, may interfere with OTU repair. We aimed to evaluate the role of CD20 + cells in the healing process of OTU in rats.Design: Wistar male rats were divided into four groups: a control group (treated with 0.1 mL/kg of saline) and three groups treated with anti-CD20 rituximab (RTX) at 2.5, 10, or 40 mg/kg 24 h before OTU production. The animals were weighed (day 0) and euthanized on days 3, 7, 14, and 21 after ulceration. With Blood cells (hematological analysis) and the traumatically induced ulcers were clinically measured. The mucosal samples were histologically (scores 0-4), histochemically (collagen assay (picrosirius)), histomorphometrically (cell counting), and immunohistochemically (CD20(+), Tumor Necrosis Factor alpha(TNF-alpha), Interleukin(IL)- 1 beta, IL-6 and alpha-smooth-muscle-actin (alpha-SMA)) analyzed. ANOVA-1-2-way/Bonferroni, Kruskal-Wallis/Dunn, and correlation analyses were performed (GraphPad Prism 5.0, p < 0.05).Results: RTX leads to leukopenia, lymphocytopenia, and neutropenia (p < 0.001), and high doses reduced the OTU area (p = 0.001), impaired histologic scores (p < 0.05), and delayed polymorphonuclear (p < 0.001) and mononuclear (p < 0.001) cells, and total (p = 0.011), type-I (p = 0.008), and type-III (p = 0.021) collagen.Conclusion: RTX treatment reduced CD20(+) cells in OTU (p = 0.001), TNF-alpha (p = 0.006), and alpha-SMA (p = 0.022) immunostaining and delayed IL-6 reduction (p = 0.006), with no influence in IL-1 beta immunostaining. CD20 + cell blockage by RTX reduced cell migration, acute inflammation, and wound healing in OTU.

Automated summary

The study aimed to evaluate the role of CD20 + cells in the healing process of oral traumatic ulcers (OTU) in rats. The results showed that blocking CD20 + cells with anti-CD20 rituximab (RTX) reduced cell migration, acute inflammation, and wound healing in OTU.